Bio-Rad Laboratories (BIO) Accounts Payables (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Accounts Payables data on file, last reported at $133.1 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 3.48% year-over-year to $133.1 million in Q1 2026; TTM through Mar 2026 was $133.1 million, a 3.48% decrease from a year earlier, with the FY2025 full-year figure at $129.0 million, up 5.48% from the prior year.
• Accounts Payables for Q1 2026 stood at $133.1 million, up from $129.0 million in the prior quarter.
• Over the last five years, Accounts Payables for BIO reached as high as $161.0 million in Q1 2023 and fell as low as $102.8 million in Q1 2024.
• Historically, Accounts Payables has averaged $135.6 million across 5 years, with a median of $135.0 million in 2022.
• Across the five-year window, Accounts Payables slumped 36.17% in 2024 and surged 34.21% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $135.0 million in 2022, then grew by 7.08% to $144.6 million in 2023, then declined by 15.42% to $122.3 million in 2024, then advanced by 5.48% to $129.0 million in 2025, then advanced by 3.18% to $133.1 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $133.1 million in Q1 2026, $129.0 million in Q4 2025, and $128.8 million in Q3 2025.